Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:IDYA NASDAQ:MLYS NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.36-2.1%$7.62$6.13▼$17.43$655.86M1.461.40 million shs901,608 shsIDYAIDEAYA Biosciences$28.29-3.2%$30.19$20.50▼$39.28$2.49B-0.04753,937 shs710,909 shsMLYSMineralys Therapeutics$23.69-5.4%$27.95$12.59▼$47.65$1.95B0.561.71 million shs4.18 million shsTARSTarsus Pharmaceuticals$59.28-1.8%$64.65$38.51▼$85.25$2.55B0.49723,906 shs370,113 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix0.00%-0.95%+5.56%+29.41%-32.47%IDYAIDEAYA Biosciences0.00%-4.00%+0.18%-14.76%+34.08%MLYSMineralys Therapeutics0.00%-24.79%-19.28%-10.91%+52.64%TARSTarsus Pharmaceuticals0.00%-0.20%-7.32%-19.08%+38.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.36-2.1%$7.62$6.13▼$17.43$655.86M1.461.40 million shs901,608 shsIDYAIDEAYA Biosciences$28.29-3.2%$30.19$20.50▼$39.28$2.49B-0.04753,937 shs710,909 shsMLYSMineralys Therapeutics$23.69-5.4%$27.95$12.59▼$47.65$1.95B0.561.71 million shs4.18 million shsTARSTarsus Pharmaceuticals$59.28-1.8%$64.65$38.51▼$85.25$2.55B0.49723,906 shs370,113 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix0.00%-0.95%+5.56%+29.41%-32.47%IDYAIDEAYA Biosciences0.00%-4.00%+0.18%-14.76%+34.08%MLYSMineralys Therapeutics0.00%-24.79%-19.28%-10.91%+52.64%TARSTarsus Pharmaceuticals0.00%-0.20%-7.32%-19.08%+38.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.75Moderate Buy$15.0079.43% UpsideIDYAIDEAYA Biosciences 2.82Moderate Buy$50.6979.17% UpsideMLYSMineralys Therapeutics 2.63Moderate Buy$49.33108.25% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6752.95% UpsideCurrent Analyst Ratings BreakdownLatest CRMD, MLYS, IDYA, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026IDYAIDEAYA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/2/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.006/1/2026MLYSMineralys Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/1/2026MLYSMineralys Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026IDYAIDEAYA Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/7/2026IDYAIDEAYA Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$52.00 ➝ $50.005/4/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.004/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.00(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$311.71M2.10$2.04 per share4.09$5.14 per share1.63IDYAIDEAYA Biosciences$218.71M11.36N/AN/A$11.67 per share2.42MLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/ATARSTarsus Pharmaceuticals$451.36M5.65N/AN/A$8.09 per share7.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix$163.05M$2.133.9246.44N/A45.25%45.57%24.76%8/6/2026 (Estimated)IDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/4/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.05N/AN/AN/AN/A-27.92%-26.98%8/11/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.14N/A20.30N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest CRMD, MLYS, IDYA, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51-$0.47+$0.04-$0.47N/AN/A5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million3/12/2026Q4 2025MLYSMineralys Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedix0.332.972.74IDYAIDEAYA BiosciencesN/A10.7410.74MLYSMineralys TherapeuticsN/A44.3344.33TARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%IDYAIDEAYA Biosciences98.29%MLYSMineralys Therapeutics84.46%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.50%IDYAIDEAYA Biosciences4.70%MLYSMineralys Therapeutics18.94%TARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.45 million75.71 millionOptionableIDYAIDEAYA Biosciences8087.86 million83.73 millionOptionableMLYSMineralys Therapeutics2882.50 million66.87 millionOptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableCRMD, MLYS, IDYA, and TARS HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street ZenJune 6 at 1:18 AM | marketbeat.comBNP Paribas Financial Markets Has $29.16 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 5 at 3:28 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 3, 2026 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 2, 2026 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 28, 2026 | globenewswire.comLisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24, 2026 | marketbeat.comUBS Group AG Has $5.48 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSMay 21, 2026 | marketbeat.comTarsus taps John Cena for its latest Demodex blepharitis campaignMay 20, 2026 | fiercepharma.comFTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMJohn Cena hops into the ring to fight demodex blepharitis for Tarsus PharmaceuticalsMay 19, 2026 | mmm-online.comMTarsus Pharmaceuticals, Inc. $TARS Stake Raised by TimesSquare Capital Management LLCMay 19, 2026 | marketbeat.comTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comCena was diagnosed with Demodex blepharitis, which he admittedly "didn't even know existed"May 14, 2026 | yahoo.comTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansMay 14, 2026 | globenewswire.comAssessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term GainsMay 13, 2026 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Tarsus Pharmaceuticals (TARS)May 11, 2026 | theglobeandmail.comIs It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?May 11, 2026 | finance.yahoo.comWhat is HC Wainwright's Estimate for TARS Q2 Earnings?May 11, 2026 | marketbeat.comLifesci Capital Has Negative Estimate for TARS Q2 EarningsMay 11, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRMD, MLYS, IDYA, and TARS Company DescriptionsCorMedix NASDAQ:CRMD$8.36 -0.18 (-2.11%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$8.32 -0.04 (-0.44%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.IDEAYA Biosciences NASDAQ:IDYA$28.29 -0.93 (-3.18%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$27.28 -1.02 (-3.59%) As of 06/5/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Mineralys Therapeutics NASDAQ:MLYS$23.69 -1.36 (-5.43%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$23.74 +0.05 (+0.21%) As of 06/5/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Tarsus Pharmaceuticals NASDAQ:TARS$59.28 -1.06 (-1.76%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$58.50 -0.77 (-1.31%) As of 06/5/2026 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
